PainQx is currently advancing our novel AI-powered objective pain measurement technology through further R&D activities to prepare for FDA validation studies in 2020. To support our strategic efforts, PainQx is seeking to build relationships with partners that share in our vision.  Our goal is to collaborate with investors, clinicians, chronic pain patients, and drug-development companies that understand the difficulties with subjective pain assessment. If you are interested in learning more about our work and how to help, please reach out to for more information.

Our Seed Investors

PainQx is proud to have been supported by a number of Seed Investors.
With their support, PainQx has been actively developing our novel technology- thank you.